Assenagon Asset Management’s Sage Therapeutics SAGE Stock Holding History

Assenagon Asset Management’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-120,723	Closed	-$656K	–	1318
2024 Q4	$656K	Sell	120,723 -65,316	-35%	-$399K	﹤0.01%	1162
2024 Q3	$1.34M	Buy	186,039 +18,814	+11%	+$172K	﹤0.01%	1073
2024 Q2	$1.82M	Buy	167,225 +10,632	+7%	+$136K	﹤0.01%	939
2024 Q1	$2.93M	Buy	156,593 +143,075	+1,058%	+$3.3M	0.01%	748
2023 Q4	$293K	Buy	+13,518	New	+$268K	﹤0.01%	1334
2023 Q3	–	Sell	-32,605	Closed	-$1.53M	–	1459
2023 Q2	$1.53M	Sell	32,605 -71,126	-69%	-$3.54M	0.01%	859
2023 Q1	$4.35M	Buy	103,731 +6,897	+7%	+$297K	0.02%	608
2022 Q4	$3.69M	Hold	96,834	–	–	0.01%	613
2022 Q3	$3.79M	Sell	96,834 -77,617	-44%	-$3M	0.01%	545
2022 Q2	$5.63M	Buy	+174,451	New	+$5.85M	0.02%	508
2021 Q4	–	Sell	-32,017	Closed	-$1.42M	–	1544
2021 Q3	$1.42M	Buy	32,017 +8,300	+35%	+$381K	﹤0.01%	813
2021 Q2	$1.35M	Buy	23,717 +7,757	+49%	+$548K	﹤0.01%	831
2021 Q1	$1.2M	Buy	+15,960	New	+$1.31M	﹤0.01%	885

Other funds holding SAGE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Assenagon Asset Management's SAGE Position: Q1 2025 in Review

Assenagon Asset Management sold out of Sage Therapeutics (SAGE) in Q1 2025, closing a stake of 120,723 shares — an estimated $656K sold.

Assenagon Asset Management first reported a position in SAGE in Q1 2021 and held it in 13 quarters. The position peaked at $5.63M in Q2 2022. 198 funds tracked by Wall St. Rank hold SAGE as of Q1 2025.

Assenagon Asset Management reported no remaining Sage Therapeutics position as of Q1 2025 after selling out during the quarter.
Assenagon Asset Management sold 120,723 Sage Therapeutics shares in Q1 2025, an estimated $656K.
Assenagon Asset Management first reported a position in Sage Therapeutics in Q1 2021 and held it in 13 quarters.
Assenagon Asset Management's Sage Therapeutics position peaked at $5.63M in Q2 2022.
198 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2025.

Based on Assenagon Asset Management's 13F filing for Q1 2025, filed 15 Apr 2025.